amyotrophic lateral sclerosis (ALS) research hub
12 indexed studies · 4 currently recruiting
- ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1, open-label, single-center study to determine the absorption, distribution, metabolism, and excretion of a single oral dose of SAR443820 containing microtracer [14C]-SAR443820 in healthy male participants
This study is looking at how a new drug called SAR443820 moves through the body in healthy men. It aims to understand how the body absorbs, uses, and gets rid of the drug, which could one day help people with ALS.
Netherlands - recruitingNA
GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
This study looks at a new brain implant called N1 and a robot, R1, for people with paralysis. It aims to see if they are safe and can help control devices like computers, offering a new way to interact with the world.
United Kingdom - recruitingNA
Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis
This study looks at how different amounts of food given through a feeding tube (PEG) affect people with ALS. We want to see if more calories can slow down the disease by keeping weight stable, as weight loss can be a problem in ALS.
Germany - recruiting
Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis
This study looks at how taste and smell might affect what people with ALS eat and their overall nutrition. It aims to understand if problems with these senses contribute to weight loss in ALS and how to help people eat better.
France - recruitingPHASE2
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
This study looks at a new treatment called PHENOGENE-1A for people with mild to moderate ALS. Researchers want to see if it can help improve daily function, breathing, and reduce inflammation, compared to a dummy treatment. You'd also keep taking your usual Riluzole.
United States · Czechia · Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
This study is testing a new medicine, AMX0035, for people with Motor Neurone Disease (ALS). It aims to see if the medicine can slow down the disease's progression over 48 weeks, compared to a dummy medicine.
Netherlands · Poland · Germany - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Randomized, Placebo-Controlled, Double-Blind, Single Dose, Phase 1 Study to Explore the PK/PD Relationship of QRL-101 in People Living With ALS
This early-stage study is looking at a new medicine called QRL-101 for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neuron Disease. It aims to understand how the medicine works in the body and what effects it might have, compared to a dummy medicine.
Netherlands - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis
This study is looking at a new medicine called ARGX-119 for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. It's an early-stage trial trying to find out if the medicine is safe, how well people tolerate it, and if it could help. Some people will get the active medicine, and others will get a dummy medicine.
Denmark · France · Netherlands - authorisedTherapeutic exploratory (Phase II)
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS)
This study is testing a new medicine, Usnoflast, for adults with Amyotrophic Lateral Sclerosis (ALS). It aims to see if the medicine can slow down the disease and if it's safe. Participants will receive either Usnoflast or a placebo (dummy medicine) for 36 weeks.
Spain · Germany · Sweden - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants
This study is looking at how three different versions of a new medicine, QRL-101, move through the bodies of healthy people. It's an early stage of testing to see how well the body takes in, processes, and gets rid of the medicine, which could eventually help people with ALS.
Netherlands - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyotrophic lateral sclerosis (fALS) and sporadic amyotrophic lateral sclerosis (sALS)
This study is testing a new medicine, AP-101, for people with ALS. We want to see if it's safe and how the body handles it. Some people will get AP-101, others a dummy medicine, then everyone gets AP-101. It will help us understand more about ALS treatments.
Sweden - active not recruitingPHASE2
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
This study is looking into a new medication called VHB937 for people with early-stage ALS. We want to see if it's safe and helps improve daily activities and breathing, compared to a dummy drug (placebo).
United States · Australia · Belgium